La maladie de Parkinson en France (serveur d'exploration) - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Enzyme Inhibitors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Enzyme Induction < Enzyme Inhibitors < Enzyme-Linked Immunosorbent Assay  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
000506 (????) O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; Werner Poewe ; F. Stocchi ; E. TolosaRasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
000524 (2006) Agnes Janoshazi [France] ; François Sellal ; Christian Marescaux ; Jean-Marie Danion ; Jean Marie Warter ; Jean De BarryAlteration of protein kinase C conformation in red blood cells: a potential marker for Alzheimer's disease but not for Parkinson's disease.
000589 (2006) Emilie Giaime [France] ; Claire Sunyach ; Magali Herrant ; Sébastien Grosso ; Patrick Auberger ; Pamela J. Mclean ; Frédéric Checler ; Cristine Alves Da CostaCaspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway.
000874 (2008) P. Damier [France] ; F. Viallet ; M. Ziegler ; I. Bourdeix ; K. ReratLevodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
000935 (2009) Alain Destée [France] ; Karin Rérat ; Isabelle BourdeixIs there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
000C60 (????) David Maltête [France] ; Anne Marie Cottard ; Bruno Mihout ; Jean CostentinErythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
000C75 (2011) Jean-Christophe Corvol [France] ; Cécilia Bonnet ; Fanny Charbonnier-Beaupel ; Anne-Marie Bonnet ; Marie-Hélène Fiévet ; Agnès Bellanger ; Emmanuel Roze ; Gayané Meliksetyan ; Mouna Ben Djebara ; Andreas Hartmann ; Lucette Lacomblez ; Cédric Vrignaud ; Noël Zahr ; Yves Agid [France] ; Jean Costentin ; Jean-Sébastien Hulot ; Marie VidailhetThe COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
000D32 (2011) Olivier Rascol [France] ; Andres Lozano ; Matthew Stern ; Werner Poewe [Autriche]Milestones in Parkinson's disease therapeutics.
000D60 (2012) Mickael Decressac [France] ; Stéphanie Pain ; Pierre-Yves Chabeauti ; Laura Frangeul ; Nathalie Thiriet ; Herbert Herzog ; Jackie Vergote ; Sylvie Chalon ; Mohamed Jaber ; Afsaneh GaillardNeuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
000E33 (????) Olivier Rascol [France] ; Paolo Barone ; Madhuri Behari ; Murat Emre ; Nir Giladi ; C Warren Olanow ; Evzen Ruzicka ; Francesco Bibbiani ; David Squillacote ; Anna Patten ; Eduardo TolosaPerampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
001548 (2014) Judith Eschbach [Allemagne, France] ; Björn Von Einem [Allemagne] ; Kathrin Müller [Allemagne] ; Hanna Bayer [Allemagne] ; Annika Scheffold [Allemagne] ; Bradley E. Morrison [États-Unis] ; K. Lenhard Rudolph [Allemagne] ; Dietmar R. Thal [Allemagne] ; Anke Witting [Allemagne] ; Patrick Weydt [Allemagne] ; Markus Otto [Allemagne] ; Michael Fauler [Allemagne] ; Birgit Liss [Allemagne] ; Pamela J. Mclean [États-Unis] ; Albert R. La Spada [États-Unis] ; Albert C. Ludolph [Allemagne] ; Jochen H. Weishaupt [Allemagne] ; Karin M. Danzer [Allemagne]Mutual exacerbation of PGC-1α deregulation and α-synuclein oligomerization
001863 (2016) Jean-Marc Taymans [France] ; Elisa Greggio [Italie]LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
001E00 (1995) P. Limousin [France] ; P. Pollak ; J P Pfefen ; C L Tournier-Gervason ; R. Dubuis ; J E PerretAcute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
001E17 (1996) P. Hantraye [France] ; E. Brouillet ; R. Ferrante ; S. Palfi ; R. Dolan ; R T Matthews ; M F BealInhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
001F44 (1998) M. Merad-Boudia [France] ; A. Nicole ; D. Santiard-Baron ; C. Saillé ; I. Ceballos-PicotMitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Enzyme Inhibitors" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Enzyme Inhibitors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Enzyme Inhibitors
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024